Inspire Medical Systems Reports Earnings Monday Against a Backdrop of Reimbursement Uncertainty

Inspire Medical Systems (INSP) reports first-quarter 2026 earnings after the close on May 4, with the stock trading at $56.70 ahead of the release. The central question: can the medical device maker sustain its remarkable streak of earnings beats—four consecutive quarters of triple-digit surprises—even as analysts project a sharp swing to a loss of $0.36 per share? With the stock down 32% from its 52-week high and technical signals flashing caution, this report will test whether INSP's obstructive sleep apnea therapy franchise can weather a challenging setup.

Part 1: Earnings Preview

Inspire Medical Systems develops and commercializes the Inspire therapy system, an implantable neurostimulation device that treats obstructive sleep apnea by stimulating the hypoglossal nerve to maintain airway patency during sleep. The company targets patients who cannot tolerate or are inadequately managed by CPAP devices, positioning itself in a large addressable market as awareness of sleep apnea treatment alternatives grows.

INSP reports Q1 2026 results after the close on May 4. Analysts expect a loss of $0.36 per share on revenue of approximately $201 million. The company most recently reported Q4 2025 earnings of $1.65 per share, crushing estimates of $0.69 and marking its fourth consecutive quarter of triple-digit percentage beats. Year-over-year, the consensus estimate represents a dramatic reversal: Q1 2025 delivered earnings of $0.10 per share, meaning analysts now project a swing to a $0.46 per share loss—a -460% decline.

Three key themes define this release:

1. Competitive Pressure from GLP-1 Drugs: Eli Lilly's Zepbound (tirzepatide) received FDA approval in late 2025 for obstructive sleep apnea, introducing pharmaceutical competition to INSP's surgical device market. Investors will scrutinize procedure volumes and physician commentary for any signs that GLP-1 therapies are slowing Inspire implant adoption, particularly among patients who may prefer medication over an invasive procedure.

2. Profitability Trajectory and Margin Sustainability: After four quarters of strong profitability, the sharp swing to an expected Q1 loss raises questions about seasonality, operating leverage, and whether the company's 15.95% net margin from Q4 can be sustained. Management guidance on full-year profitability—analysts project $1.82 for 2026, down 25% from 2025's $2.42—will be critical.

3. Revenue Growth Deceleration: Q4 2025 revenue grew just 12.2% year-over-year, the slowest pace in recent quarters. With Q1 revenue expected flat to slightly up versus the prior year, investors need clarity on whether this reflects market saturation, reimbursement headwinds, or temporary factors. The company's ability to reaccelerate growth will determine whether the current valuation—trading at 20.9x trailing earnings—is justified.

Analyst commentary ahead of the release reflects caution. Multiple firms downgraded INSP following the GLP-1 approval, with Oppenheimer cutting its rating from Outperform to Market Perform in January. UBS set a $67 price target, while Truist lowered its target to $64, both citing competitive uncertainty. The consensus has shifted toward a Hold stance, with 11 of 17 analysts now neutral and the average price target of $73.17 implying just 29% upside from current levels.

Part 2: Historical Earnings Performance

Inspire Medical Systems has established an exceptional track record of exceeding expectations, beating analyst estimates in 30 of its last 32 quarterly reports—a 94% positive surprise ratio. The most recent four quarters showcase this pattern vividly: Q1 2025 delivered $0.10 versus an expected loss of $0.23 (143% beat), Q2 2025 posted $0.45 against $0.22 estimates (105% beat), Q3 2025 reported $0.38 versus a projected loss of $0.15 (353% beat), and Q4 2025 crushed with $1.65 against $0.69 consensus (139% beat).

The magnitude of these surprises has been extraordinary, with the last four quarters averaging a 185% beat rate. This consistent outperformance reflects either conservative analyst modeling, the company's ability to exceed internal guidance, or both. However, the pattern also raises the bar: with analysts now projecting a $0.36 loss for Q1 2026, investors will watch whether management can deliver another upside surprise or if the competitive and seasonal headwinds finally catch up to estimates.

The year-over-year comparison is particularly stark. Q1 2025's $0.10 profit represented a significant achievement, but the current $0.36 loss estimate suggests analysts expect meaningful first-quarter seasonality or one-time factors. Whether INSP can beat this lowered bar—and by how much—will significantly influence post-earnings sentiment, especially given the stock's recent technical weakness.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Inspire Medical Systems typically reports earnings after the market close, meaning Day 0 reflects anticipation and after-hours reaction, while Day +1 captures the first full trading session response.

Historical price behavior around INSP earnings reveals extreme volatility, with an average absolute Day +1 move of 16.09%—more than double the average Day 0 move of 1.37%. The most recent release on February 11, 2026, exemplifies this pattern: despite a strong earnings beat, the stock dropped 12.55% the following day, suggesting investors focused on forward guidance or competitive concerns rather than the quarterly result itself.

The volatility has been asymmetric and unpredictable. August 2025 saw a brutal 32.35% Day +1 decline despite a modest 3.05% Day 0 gain, while November 2025 delivered a 15.33% Day +1 surge following positive results. The largest single-day move came in May 2024, when the stock plunged 33.47% after earnings, and August 2024's 28.14% rally. This 13.39% average Day +1 range indicates that INSP regularly experiences double-digit intraday swings on earnings days.

Investors should prepare for significant post-earnings movement in either direction. The stock's tendency to gap sharply on Day +1—often in the opposite direction of the initial after-hours reaction—suggests that guidance, management commentary, and competitive positioning matter more than the headline numbers. With the stock already under pressure and trading near 52-week lows, the setup for a volatile reaction is firmly in place.

Part 2.2: Options Market Expected Move

The options market is pricing a 15.83% expected move through the May 15 expiration (14 days out), implying a range of $47.72 to $65.68. This expected move is slightly below the stock's 16.09% average historical Day +1 earnings move, suggesting options traders are pricing in significant volatility but not quite the extreme swings INSP has delivered in recent quarters. Given the stock's history of 20%+ single-day moves and the elevated uncertainty around GLP-1 competition, the options market may be underpricing the true risk of an outsized reaction.

Part 3: What Analysts Are Saying

Analyst sentiment on Inspire Medical Systems has deteriorated significantly, with the consensus average recommendation standing at 3.71 (between Hold and Buy, but closer to Hold). The rating distribution shows 6 Strong Buys, 0 Moderate Buys, 11 Holds, 0 Moderate Sells, and 0 Strong Sells among 17 analysts covering the stock. This represents a notable shift from one month ago, when 7 analysts rated it a Strong Buy and only 10 held neutral stances.

The average price target of $73.17 implies approximately 29% upside from the current price of $56.70, but the wide range of targets—from a low of $56.00 to a high of $120.00—reflects deep disagreement about the company's prospects. The low-end target sits essentially at the current price, suggesting at least one analyst sees limited near-term upside, while the high-end target implies more than doubling from current levels.

The deteriorated sentiment trend is particularly notable given the timing: multiple downgrades followed Eli Lilly's GLP-1 approval for sleep apnea in late 2025, with firms like Oppenheimer moving from Outperform to Market Perform. The shift from 7 Strong Buys to 6, combined with the increase in Hold ratings from 10 to 11, signals growing caution among the analyst community. With nearly two-thirds of analysts now neutral or negative, the consensus has clearly moved toward a wait-and-see posture ahead of this critical earnings report.

Part 4: Technical Picture

The Barchart Technical Opinion for Inspire Medical Systems shows an 88% Sell signal, unchanged from last week but improved from last month's 100% Sell reading. This strong bearish signal reflects significant technical deterioration as the stock approaches a critical earnings catalyst.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum remains negative but less extreme than longer timeframes
• Medium-term (100% Sell): Maximum bearish reading suggests intermediate-term trend damage is severe and unambiguous
• Long-term (100% Sell): Maximum bearish signal reflects sustained weakness in the primary trend structure

Trend Characteristics: The technical environment shows Average strength with the Weakest directional momentum, indicating a downtrend that lacks conviction but continues to pressure the stock lower heading into earnings.

The moving average structure confirms the bearish setup. INSP trades at $56.70, above its 5-day ($55.29), 10-day ($55.23), and 20-day ($55.37) moving averages, suggesting a very short-term stabilization attempt. However, the stock remains below its 50-day ($56.78), 100-day ($73.86), and 200-day ($83.25) moving averages, with the longer-term averages showing significant distance from current price. The 100-day and 200-day moving averages sit 30% and 47% above the current price, respectively, illustrating the magnitude of the stock's decline from its highs.

The technical setup heading into earnings is decidedly cautious. While the stock has found short-term support just above $55 and stabilized over the past few weeks, the broader trend structure remains broken. The 50-day moving average at $56.78 represents immediate overhead resistance, and the stock's failure to reclaim this level suggests buyers lack conviction. With the stock trading near its 52-week low of $48.30 and all major moving averages in bearish alignment, INSP enters earnings with minimal technical support. Any disappointment on guidance or competitive commentary could quickly push the stock toward new lows, while a strong beat would need to be accompanied by compelling forward commentary to trigger a sustained reversal of the damaged trend structure.